PETER HOTEZ to Adjuvants, Immunologic
This is a "connection" page, showing publications PETER HOTEZ has written about Adjuvants, Immunologic.
Connection Strength
2.573
-
The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
Score: 0.745
-
Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
Score: 0.159
-
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
Score: 0.153
-
COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
Score: 0.143
-
A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
Score: 0.113
-
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
Score: 0.110
-
The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis. 2016 07; 10(7):e0004797.
Score: 0.108
-
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
Score: 0.084
-
Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infect Immun. 2010 Apr; 78(4):1552-63.
Score: 0.069
-
Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response. Vaccine. 2026 Mar 19; 76:128296.
Score: 0.053
-
Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 Dec; 18(12):e0012788.
Score: 0.049
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
Score: 0.049
-
Vaccination of dogs with a recombinant cysteine protease from the intestine of canine hookworms diminishes the fecundity and growth of worms. J Infect Dis. 2004 May 15; 189(10):1952-61.
Score: 0.046
-
Effect of vaccination with a recombinant fusion protein encoding an astacinlike metalloprotease (MTP-1) secreted by host-stimulated Ancylostoma caninum third-stage infective larvae. J Parasitol. 2003 Aug; 89(4):853-5.
Score: 0.044
-
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
Score: 0.043
-
Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon. PLoS One. 2022; 17(9):e0275013.
Score: 0.042
-
Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-na?ve adults. Vaccine. 2022 10 06; 40(42):6084-6092.
Score: 0.042
-
Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl Trop Dis. 2022 09; 16(9):e0010258.
Score: 0.042
-
Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
Score: 0.039
-
Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Negl Trop Dis. 2019 09; 13(9):e0007730.
Score: 0.034
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.034
-
IgG Induced by Vaccination With Ascaris suum Extracts Is Protective Against Infection. Front Immunol. 2018; 9:2535.
Score: 0.032
-
Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. PLoS Negl Trop Dis. 2018 10; 12(10):e0006772.
Score: 0.032
-
Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Hum Vaccin Immunother. 2019; 15(1):210-219.
Score: 0.032
-
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
Score: 0.029
-
Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2017 05; 11(5):e0005574.
Score: 0.029
-
Vaccination with alum-precipitated recombinant Ancylostoma-secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. J Infect Dis. 1996 Dec; 174(6):1380-3.
Score: 0.028
-
Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection. PLoS Negl Trop Dis. 2016 Apr; 10(4):e0004586.
Score: 0.027
-
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016 04 02; 12(4):976-87.
Score: 0.026
-
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
Score: 0.025
-
New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. Hum Vaccin Immunother. 2015; 11(5):1251-7.
Score: 0.024
-
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58.
Score: 0.023
-
Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
Score: 0.021
-
Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis. 2012; 6(3):e1564.
Score: 0.020
-
The impact of concurrent and treated Ancylostoma ceylanicum hookworm infections on the immunogenicity of a recombinant hookworm vaccine in hamsters. J Infect Dis. 2006 Jan 01; 193(1):155-62.
Score: 0.013
-
Immunogenicity of the hookworm Na-ASP-2 vaccine candidate: characterization of humoral and cellular responses after vaccination in the Sprague Dawley rat. Hum Vaccin. 2005 May-Jun; 1(3):123-8.
Score: 0.013